Dermata Therapeutics files 1-for-16 reverse stock split, effective March 14, 2023

Dermata Therapeutics, Inc.

Board approved a 1-for-16 reverse split of common stock on March 8; filed with Delaware on March 13.
Split effective 12:01 a.m. ET on March 14, 2023; Nasdaq trading begins on split-adjusted basis same day.
No fractional shares issued; stockholders receive cash in lieu of any fractional interest.
CUSIP number for common stock changes to 249845306.
All outstanding options and warrants adjusted proportionally; authorized shares unchanged.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Dermata Therapeutics, Inc.: Effect a 1-for-16 reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-03-14).

Change: charter amendment
Effective: 2023-03-14

Exact text from the filing

On March 13, 2023, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on March 14, 2023, a 1-for-16 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

Browse all governance changes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-002711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.